PMID- 31477526
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 2588-9311 (Electronic)
IS  - 2588-9311 (Linking)
VI  - 4
IP  - 3
DP  - 2021 Jun
TI  - Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell 
      Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial 
      Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI 
      Era.
PG  - 502-505
LID - S2588-9311(19)30117-8 [pii]
LID - 10.1016/j.euo.2019.07.014 [doi]
AB  - Pazopanib is an oral angiogenesis tyrosine kinase inhibitor (TKI) recommended in 
      metastatic renal cell carcinoma (mRCC) for treatment-naive patients or those 
      experiencing cytokine failure. We conducted a phase 2, open-label, single-arm 
      study in ten Spanish centres among mRCC patients whose disease progressed on 
      first-line TKI. Patients received pazopanib until disease progression, death, or 
      unacceptable toxicity. Twenty-seven patients were included (median age 62yr, 
      51.9% male). The objective overall response rate was 14.8% (95% confidence 
      interval [CI] 1.4-28.2%). Median progression-free survival was 6.7mo (95% CI 
      3.7-11.2) and median overall survival was 20.6mo (95% CI 12.6-27.4). Lower 
      circulating levels of IL-10 (p=0.002) were observed in responding patients at 8 
      wk after treatment. The median pazopanib treatment duration was 6.0mo (range 
      1.0-47.0). Most patients (48.1%) had mild or moderate adverse events (AEs), while 
      44.4% had severe AEs. Pazopanib was clinically active and well tolerated as a 
      second-line treatment in mRCC patients after TKI failure, and circulating IL-10 
      levels could predict response. PATIENT SUMMARY: Pazopanib could be used as a 
      second-line therapy for the treatment of metastatic renal cell carcinoma after 
      failure of tyrosine kinase inhibitor (TKI) therapy when drugs such as nivolumab 
      and cabozantinib are not available. Now that immunotherapy plus antiangiogenic 
      therapy is a first-line option, IL-10 levels deserve further exploration as a 
      potential predictor of response to sequential TKI-TKI therapy.
CI  - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All 
      rights reserved.
FAU - Bellmunt, Joaquim
AU  - Bellmunt J
AD  - University Hospital del Mar, Barcelona, Spain. Electronic address: 
      jbellmunt@parcdesalutmar.cat.
FAU - Esteban, Emilio
AU  - Esteban E
AD  - Hospital Universitario Central de Asturias, Oviedo, Spain.
FAU - Del Muro, Xabier Garcia
AU  - Del Muro XG
AD  - Instituto Catalan de Oncologia, IDIBELL, Barcelona, Spain.
FAU - Sepulveda, Juan Manuel
AU  - Sepulveda JM
AD  - Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Maroto, Pablo
AU  - Maroto P
AD  - Hospital de Sant Pau, Barcelona, Spain.
FAU - Gallardo, Enrique
AU  - Gallardo E
AD  - Institut d'Investigacio i Innovacio Parc Tauli, Parc Tauli Hospital Universitari, 
      Barcelona, Spain.
FAU - Del Alba, Aranzazu Gonzalez
AU  - Del Alba AG
AD  - Servicio de Oncologia Medica, Hospital Universitario Son Dureta, Palma de 
      Mallorca, Spain.
FAU - Etxaniz, Olatz
AU  - Etxaniz O
AD  - Instituto Catalan de Oncologia, Badalona, Spain.
FAU - Guix, Marta
AU  - Guix M
AD  - University Hospital del Mar, Barcelona, Spain.
FAU - Larriba, Jose Luis Gonzalez
AU  - Larriba JLG
AD  - Hospital Clinico San Carlos, Madrid, Spain.
FAU - Arranz, Jose A
AU  - Arranz JA
AD  - Hospital Gregorio Maranon, Madrid, Spain.
FAU - Redrado, Miriam
AU  - Redrado M
AD  - CIBERONC/IDISNA Program of Solid Tumours and Biomarkers, CIMA and Department of 
      Histology and Pathology, School of Medicine, University of Navarra, Pamplona, 
      Spain.
FAU - Calvo, Alfonso
AU  - Calvo A
AD  - CIBERONC/IDISNA Program of Solid Tumours and Biomarkers, CIMA and Department of 
      Histology and Pathology, School of Medicine, University of Navarra, Pamplona, 
      Spain.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190830
PL  - Netherlands
TA  - Eur Urol Oncol
JT  - European urology oncology
JID - 101724904
RN  - 0 (Biomarkers)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
SB  - IM
MH  - Biomarkers
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Indazoles
MH  - *Kidney Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Pyrimidines
MH  - Sulfonamides
OTO - NOTNLM
OT  - Biomarkers
OT  - Kidney cancer
OT  - Objective overall response rate
OT  - Overall survival
OT  - Progression-free survival
EDAT- 2019/09/04 06:00
MHDA- 2022/02/02 06:00
CRDT- 2019/09/04 06:00
PHST- 2019/06/04 00:00 [received]
PHST- 2019/07/19 00:00 [accepted]
PHST- 2019/09/04 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2019/09/04 06:00 [entrez]
AID - S2588-9311(19)30117-8 [pii]
AID - 10.1016/j.euo.2019.07.014 [doi]
PST - ppublish
SO  - Eur Urol Oncol. 2021 Jun;4(3):502-505. doi: 10.1016/j.euo.2019.07.014. Epub 2019 
      Aug 30.